Accelerator · 6 deals
A national incubator intended to help turn early-stage infectious disease research into investable commercial ventures.
Every published round Biointelect Venturer took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted, and a place in one of its own programs is under Cohorts.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| ENA Respiratory | Grant | 1 Sep 2026 | $3m | Lead | fundedstartupsdaily.com (16 Sep 2026), fundedstartupsdaily.com (15 Sep 2026), Uniseed, Startup Daily, Biotech Dispatch, datapile.co (3 Sep 2026), Brandon Capital (2 Sep 2026), Dealroom, datapile.co (7 Aug 2026), Brandon BioCatalyst (6 Sep 2024), Brandon Capital (30 Apr 2024), Brandon BioCatalyst (29 Apr 2024), Brandon Capital portfolio | |
| SAMMvax | Accelerator | 30 Aug 2026 | - | Lead | Startup Daily, Biotech Dispatch | |
| Saccharide Therapeutics | Accelerator | 30 Aug 2026 | - | Lead | Startup Daily, Biotech Dispatch | |
| Proboxis Biotechnology | Accelerator | 30 Aug 2026 | $1.5m | Lead | Mirage News, Startup Daily, Biotech Dispatch | |
| Ebivanta Therapeutics | Accelerator | 30 Aug 2026 | $1.5m | Lead | Mirage News, Startup Daily, Biotech Dispatch | |
| AdaptiVax | Accelerator | 30 Aug 2026 | - | Lead | Startup Daily, Biotech Dispatch |
Everyone Biointelect Venturer has named to a program in published coverage. A place in a program is not a raise: the cheque is the figure recorded with the place, which is the program's standard terms where we hold them, and a blank is one we don't.
| Member | Program | Announced | Cheque | Sources |
|---|---|---|---|---|
| ENA Respiratory | - | 31 Aug 2026 | $8.3m | Uniseed, Startup Daily, Brandon Capital, Dealroom |
| ENA Respiratory | The Venturer | 30 Aug 2026 | $8.3m | Biotech Dispatch (3 Sep 2026), Biotech Dispatch (31 Aug 2026) |
Companies Biointelect Venturer has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| ENA Respiratory | Antiviral nasal spray to prevent severe respiratory viral infections | 30 Aug 2026, Accelerator | 2 | 2 |
| AdaptiVax | Working on a virus-like particle vaccine platform initially targeting RSV, human metapneu… | 30 Aug 2026, Accelerator | 1 | 1 |
| Ebivanta Therapeutics | Developing an mRNA vaccine against Epstein–Barr virus. | 30 Aug 2026, Accelerator | 1 | 1 |
| Proboxis Biotechnology | Developing a vaccine production platform for mosquito-borne viruses, beginning with Japan… | 30 Aug 2026, Accelerator | 1 | 1 |
| Saccharide Therapeutics | Advancing ST101, a malaria vaccine designed to target a structure that remains consistent… | 30 Aug 2026, Accelerator | 1 | 1 |
| SAMMvax | Received support for TriVax, a trivalent vaccine designed to provide broad protection aga… | 30 Aug 2026, Accelerator | 1 | 1 |
Fund closes reported for Biointelect Venturer, as distinct from the investments it has made.
Companies Biointelect Venturer has backed that another company then bought. An exit for the holding, not a deal Biointelect Venturer did.
| Name | Role | Sources |
|---|---|---|
| Danielle Shand | General Manager | Uniseed, Startup Daily, Brandon Capital, Biotech Dispatch |
| Leah Goodman | Chief Executive (former) | Biotech Dispatch |
Stories naming Biointelect Venturer. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech ENA Respiratory has begun dosing participants in the second part of its Phase IIa trial of INNA-051; its investor lineup, past government funding awards and BLUE KNIGHT alumni status are recapped.
UQ spinout Proboxis Biotechnology has received $1.5 million via the first round of the Biointelect Venturer incubator to advance a vaccine platform against mosquito-borne diseases toward human clinical development.
QIMR Berghofer's Ebivanta Therapeutics wins $1.5 million plus backing from biotech incubator Biointelect Venturer's first cohort to ready its mRNA vaccine against Epstein-Barr virus for clinical testing.
Australian biotech ENA Respiratory, whose INNA-051 nasal spray targets respiratory viruses, has been granted $2.98 million via the Biointelect Venturer program to fund a trial in adults with asthma.
An Australian infectious-disease incubator has selected six local biotechs to divide $10.48 million from its inaugural funding round, pairing non-dilutive cash with commercialisation support; the program is backed by an earlier MRFF grant.
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com